Alliance Global Partners Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners analyst James Molloy reiterated a Buy rating on Abeona Therapeutics (NASDAQ:ABEO) and maintained a $20 price target.
May 24, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alliance Global Partners analyst James Molloy reiterated a Buy rating on Abeona Therapeutics and maintained a $20 price target.
The reiteration of a Buy rating and maintenance of a $20 price target by Alliance Global Partners analyst James Molloy indicates a positive outlook for Abeona Therapeutics. This news is likely to have a positive short-term impact on the stock price as it shows confidence in the company's potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100